Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Elraglusib Oral Tablets
Elraglusib · 1 trial · 1 indication
Dose escalation/de-escalation decisions and the MTD will be determined at the end of Cycle 1 (each cycle is 21/28days).
| Arm | Type | Description |
|---|---|---|
| Elraglusib Monotherapy Dose escalation/de-escalation | EXPERIMENTAL | Elraglusib 250 mg tablets will be administered once daily with food in 21-day cycles. DG-1: 125mg (Days 1, 3, 5 of a 21 day cycle) DG1: (Starting Dose) 125 mg/QD for 21 days DG2: 250mg/QD for 21 days DG3: 500mg QD for 21 days DG4: 750mg/QD for 21 days, Dosing will continue until MTD or MED is identified. Any higher dose levels which are explored will not exceed 50% increment relative to the prior cohort rounded down to the nearest 250 mg dose (or 125 mg dose if necessary). |
| Name | Type | Description |
|---|---|---|
| Elraglusib Oral Tablets | DRUG | Elraglusib Oral Tablet, 250 mg |
Inclusion Criteria: * Participants must meet all of the following criteria to be eligible for inclusion in the study: 1. Able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan,...
Elraglusib is an investigational small molecule being developed for the treatment of advanced malignant solid tumors. It is currently in Phase 1 clinical development, and the drug has not yet been approved by the FDA. Elraglusib is also known as Elraglusib Oral Tablets.
Elraglusib is being developed by Actuate Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol ACTU. The company is conducting clinical trials to evaluate the drug's safety and preliminary anti-tumor activity in adult participants with advanced solid tumors.
Elraglusib is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA for any use. The drug has received FDA designations for rare pediatric disease and orphan drug status, reflecting its potential in treating serious conditions.
Elraglusib is being studied in a Phase 1 clinical trial with the identifier NCT07714395. The trial is titled 'Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors' and is designed to enroll 100 participants aged 18 years and older. The trial is not yet recruiting.
Yes, Elraglusib is also known as Elraglusib Oral Tablets. The drug is administered orally as a tablet formulation. This alternative name is used in clinical and regulatory contexts to specify the dosage form of the investigational therapy.